Akero Therapeutics, Inc. (AKRO) |
|
46.86 1.24 (2.72%)
|
09-27 16:00 |
|
Open: |
45.58 |
Pre. Close: |
45.62 |
|
High:
|
47.5 |
Low:
|
45.215 |
|
Volume:
|
826,233 |
Market Cap:
|
2,606(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:17:34 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 58.88 One year: 62.8 |
| Support: |
Support1: 44.99 Support2: 37.43 |
| Resistance: |
Resistance1: 50.41 Resistance2: 53.77 |
| Pivot: |
49.02  |
| Moving Average: |
MA(5): 46.44 MA(20): 49.22
MA(100): 47.25 MA(250): 44.81 |
| MACD: |
MACD(12,26): -0.3 Signal(9): 0.4 |
| Stochastic oscillator: |
%K(14,3): 10.8 %D(3): 7.8 |
| RSI: |
RSI(14): 43.8 |
| 52-week: |
High: 58.38 Low: 27.79 |
| Average Vol(K): |
3-Month: 701 (K) 10-Days: 1,228 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AKRO ] has closed above bottom band by 25.4%. Bollinger Bands are 12.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
46.8 - 47.11 |
47.11 - 47.39 |
|
Low:
|
44.26 - 44.65 |
44.65 - 45.01 |
|
Close:
|
45.02 - 45.63 |
45.63 - 46.19 |
|
Company Description |
|
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. |
Headline News |
Tue, 26 Sep 2023
3 Best Stocks to Buy Now, 9/26/2023, According to Top Analysts - Nasdaq
Mon, 25 Sep 2023
Health Canada Approves Evkeeza for Treatment of Homozygous ... - Best Stocks
Sat, 23 Sep 2023
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Consensus ... - MarketBeat
Fri, 22 Sep 2023
Is Akero Therapeutics Inc (AKRO) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Wed, 20 Sep 2023
Short Interest in Akero Therapeutics Rises 8% in August, Analysts ... - Best Stocks
Tue, 19 Sep 2023
Nonalcoholic Steatohepatitis (NASH) Market: Breakthrough Forecast ... - Digital Journal
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
56 (M) |
| Shares Float |
46 (M) |
|
% Held by Insiders
|
6.5 (%) |
|
% Held by Institutions
|
87.7 (%) |
|
Shares Short
|
6,330 (K) |
|
Shares Short P.Month
|
5,760 (K) |
Stock Financials |
|
EPS
|
-2.36 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
11.1 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-18.6 |
|
Return on Equity (ttm)
|
-30.3 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.27 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-97 (M) |
|
Levered Free Cash Flow
|
-59 (M) |
Stock Valuations |
|
PE Ratio
|
-19.86 |
|
PEG Ratio
|
1.2 |
|
Price to Book value
|
4.22 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-26.82 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
